The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | METalmark: amivantamab and capmatinib in advanced NSCLC
Alexander Spira, MD, PhD, Virginia Cancer Specialist, Fairfax, VA, discusses the Phase I/II METalmark study (NCT05488314) of amivantamab, an EGFR-MET bispecific antibody, in combination with capmatinib in patients with advanced non-small cell lung cancer (NSCLC). Whilst amivantamab has been used to target EGFR-mutated NSCLC, the addition of MET inhibition addresses MET overexpression and exon 14 skipping mutations, which are key mechanisms of resistance. The study demonstrated promising activity with the drug combination and showed no unexpected adverse events, offering potential for future therapeutic strategies. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
